阐明氯法齐明在治疗结核病中的作用。
Elucidating the role of clofazimine for the treatment of tuberculosis.
作者信息
O'Donnell M R, Padayatchi N, Metcalfe J Z
机构信息
Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Medical Center, New York City, USA; Department of Epidemiology, Mailman School of Public Health, Columbia University Medical Center, New York City, New York, USA; CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
CAPRISA MRC-HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
出版信息
Int J Tuberc Lung Dis. 2016 Dec 1;20(12):52-57. doi: 10.5588/ijtld.16.0073.
Clofazimine (CFZ), a riminophenazine and a key component of the treatment regimen for lepromatous leprosy, has been rehabilitated clinically for the treatment of multidrug-resistant tuberculosis (MDR-TB). Observational studies and a randomized control trial suggest efficacy in the treatment of MDR-TB and the potential for treatment shortening. Animal and translational research have shown mixed results. In this article, we review key clinical, animal, and translational data to better understand the potential role of CFZ in the treatment of MDR-TB and in shortening anti-tuberculosis treatment.
氯法齐明（CFZ）是一种吩嗪类药物，也是瘤型麻风治疗方案的关键组成部分，目前已在临床上重新用于治疗耐多药结核病（MDR-TB）。观察性研究和一项随机对照试验表明，其在治疗耐多药结核病方面有效，且有缩短治疗时间的潜力。动物研究和转化研究结果不一。在本文中，我们回顾了关键的临床、动物和转化研究数据，以更好地了解氯法齐明在治疗耐多药结核病及缩短抗结核治疗时间方面的潜在作用。
Zotero 插件